Aushon Appoint New Chief Scientific Officer
News Nov 24, 2010
Dr. Beushausen brings more than a quarter century of scientific research and product development experience to this new role, most recently as the Molecular Medicine Site Lead for Pfizer. Inc. He has served in a number of other senior-level scientific research positions throughout his career, including Senior Director and Global Lead, Proteomics and Reverse Pharmacology, and Director of the Toxicoproteomics Center of Emphasis in Drug Safety (Pfizer), as well as Director of Manufacturing Technologies (Invitrogen).
As Chief Scientific Officer, Dr. Beushausen will be responsible for driving Aushon’s existing and future research and development programs through to successful market entry and adoption. He will also be relied on for creating and implementing the company’s overall scientific strategy.
“We are thrilled to welcome Dr. Beushausen to Aushon at such an exciting time in our evolution,” says Pete Honkanen, President and CEO of Aushon. “His experience in both basic and applied research, together with his ability to understand how our technology can be best utilized in a clinical research setting, will play a pivotal role in shaping our product positioning and platform development, as well as in helping to establish and implement our technical and corporate strategy moving forward. Furthermore, Dr. Beushausen’s reputation as a thought leader will help us strengthen our growing relevance to both our customers and within the scientific community.”
A simple blood test reliably detects signs of brain damage in people on the path to developing Alzheimer’s disease – even before they show signs of confusion and memory loss, according to a new study from Washington University School of Medicine in St. Louis and the German Center for Neurodegenerative Diseases in Germany.READ MORE